Skip to main content
SpringerLink
Log in

Novartis Oncology have issued a letter alerting healthcare providers of new safety information, including a boxed warning, for Exjade

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Novartis.Important information about Exjade (Rm) (deferasirox) tabelts for oral suspension. Internet Document: [6 pages], 17 Feb 2010. Available from: URL: http://www.fda.gov

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Novartis Oncology have issued a letter alerting healthcare providers of new safety information, including a boxed warning, for Exjade. React. Wkly. 1290, 4 (2010). https://doi.org/10.2165/00128415-201012900-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201012900-00009

Keywords

Search

Navigation